The following article requires a subscription:



(Format: HTML, PDF)

: The efficacy of pegfilgrastim /- chemotherapy for mobilizing stem cells in patients with solid tumours was assessed. In cycle 0, a 14-day prechemotherapy cycle, patients (N=61) were randomized open-label to single doses of pegfilgrastim (6, 12 or 18mg) on day 1, or daily filgrastim (10 [mu]g/kg) for <=7 days. Mean peak peripheral CD34 cell counts increased with pegfilgrastim dose, but were significantly higher than filgrastim only at the 18mg dose (10.17 vs 4.96 x 104/ml; P=0.014). In the clinically relevant period of days 3-7, both 12 and 18mg pegfilgrastim doses produced significantly higher peak CD34 counts (8.18 and 9.96 vs 4.51 x 104/ml for filgrastim; P=0.034 and 0.006). In cycle 1, patients received carboplatin/paclitaxel on day 1, followed from day 2 by pegfilgrastim 6-18mg or daily filgrastim (5 [mu]g/ kg/day for <=14 days) as per randomization in cycle 0. There were no significant differences in mean peak CD34 count between pegfilgrastim and filgrastim, but there was an advantage for pegfilgrastim 18mg in the relevant period of days 7-12 (3.14 vs 1.19 x 104/ml; P=0.043). A single pegfilgrastim dose (>=6mg) could be substituted for daily filgrastim in cytokine-only peripheral CD34 cell mobilization.

Bone Marrow Transplantation (2009) 43, 927-934; doi:10.1038/bmt.2008.411; published online 26 January 2009

Copyright (C) 2009 Nature Publishing Group